Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Breast Carcinoma In Situ 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Bone Density × Clear all
NCT07466498 2026-03-12

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

University of Washington

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

University of Kansas Medical Center

Phase 2 Not yet recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡